Thermo Fisher Scientific Inc.

TMO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMO.NE stands at 211.77B. In comparison, EDT.TO has a market cap of 250.90M. Regarding current trading prices, TMO.NE is priced at $14.82, while EDT.TO trades at $0.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMO.NE currently has a P/E ratio of 23.16, whereas EDT.TO's P/E ratio is -17.60. In terms of profitability, TMO.NE's ROE is N/A, compared to EDT.TO's ROE of +0.61%. Regarding short-term risk, TMO.NE is more volatile compared to EDT.TO. This indicates potentially higher risk in terms of short-term price fluctuations for TMO.NE.

TMO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMO.NE stands at 211.77B. In comparison, AKU.TO has a market cap of 45.15M. Regarding current trading prices, TMO.NE is priced at $14.82, while AKU.TO trades at $0.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMO.NE currently has a P/E ratio of 23.16, whereas AKU.TO's P/E ratio is -0.14. In terms of profitability, TMO.NE's ROE is N/A, compared to AKU.TO's ROE of -5.50%. Regarding short-term risk, TMO.NE is less volatile compared to AKU.TO. This indicates potentially lower risk in terms of short-term price fluctuations for TMO.NE.

TMO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMO.NE stands at 211.77B. In comparison, SONA.CN has a market cap of 33.59M. Regarding current trading prices, TMO.NE is priced at $14.82, while SONA.CN trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMO.NE currently has a P/E ratio of 23.16, whereas SONA.CN's P/E ratio is -10.33. In terms of profitability, TMO.NE's ROE is N/A, compared to SONA.CN's ROE of -2.51%. Regarding short-term risk, TMO.NE is less volatile compared to SONA.CN. This indicates potentially lower risk in terms of short-term price fluctuations for TMO.NE.

TMO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMO.NE stands at 211.77B. In comparison, BUX.CN has a market cap of 25.45M. Regarding current trading prices, TMO.NE is priced at $14.82, while BUX.CN trades at $0.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMO.NE currently has a P/E ratio of 23.16, whereas BUX.CN's P/E ratio is -14.00. In terms of profitability, TMO.NE's ROE is N/A, compared to BUX.CN's ROE of +2.24%. Regarding short-term risk, TMO.NE is more volatile compared to BUX.CN. This indicates potentially higher risk in terms of short-term price fluctuations for TMO.NE.

TMO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMO.NE stands at 211.77B. In comparison, IZO.CN has a market cap of 18.49M. Regarding current trading prices, TMO.NE is priced at $14.82, while IZO.CN trades at $0.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMO.NE currently has a P/E ratio of 23.16, whereas IZO.CN's P/E ratio is -7.00. In terms of profitability, TMO.NE's ROE is N/A, compared to IZO.CN's ROE of +0.47%. Regarding short-term risk, TMO.NE is less volatile compared to IZO.CN. This indicates potentially lower risk in terms of short-term price fluctuations for TMO.NE.

TMO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMO.NE stands at 211.77B. In comparison, SZLS.TO has a market cap of 4.94M. Regarding current trading prices, TMO.NE is priced at $14.82, while SZLS.TO trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMO.NE currently has a P/E ratio of 23.16, whereas SZLS.TO's P/E ratio is -0.25. In terms of profitability, TMO.NE's ROE is N/A, compared to SZLS.TO's ROE of +0.13%. Regarding short-term risk, TMO.NE is more volatile compared to SZLS.TO. This indicates potentially higher risk in terms of short-term price fluctuations for TMO.NE.

TMO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMO.NE stands at 211.77B. In comparison, MEDV.NE has a market cap of 810576.00. Regarding current trading prices, TMO.NE is priced at $14.82, while MEDV.NE trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMO.NE currently has a P/E ratio of 23.16, whereas MEDV.NE's P/E ratio is -0.09. In terms of profitability, TMO.NE's ROE is N/A, compared to MEDV.NE's ROE of +0.09%. Regarding short-term risk, TMO.NE is less volatile compared to MEDV.NE. This indicates potentially lower risk in terms of short-term price fluctuations for TMO.NE.

TMO.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMO.NE stands at 211.77B. In comparison, SCRN.CN comparison data is unavailable. Regarding current trading prices, TMO.NE is priced at $14.82, while SCRN.CN trades at N/A.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMO.NE currently has a P/E ratio of 23.16, whereas SCRN.CN's P/E ratio is N/A. In terms of profitability, TMO.NE's ROE is N/A, compared to SCRN.CN's ROE of -14.30%. Regarding short-term risk, Volatility data is not available for a full comparison. TMO.NE has daily volatility of 2.40 and SCRN.CN has daily volatility of N/A.